Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

NCT01004380 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: Farletuzumab, Carboplatin, and PLD

Sponsor

Morphotek